Enliven Therapeutics (NASDAQ:ELVN) Director Lori Anne Kunkel Sells 10,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the transaction, the director directly owned 41,884 shares of the company’s stock, valued at approximately $2,114,723.16. This trade represents a 19.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Lori Anne Kunkel also recently made the following trade(s):

• On Friday, June 5th, Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $34.54, for a total transaction of $345,400.00.

Enliven Therapeutics Stock Down 0.2%

Shares of Enliven Therapeutics stock opened at $50.80 on Thursday. Enliven Therapeutics, Inc. has a 12-month low of $14.78 and a 12-month high of $52.39. The company has a market capitalization of $3.09 billion, a price-to-earnings ratio of -30.42 and a beta of 0.24. The firm’s 50-day moving average price is $42.94 and its two-hundred day moving average price is $34.37.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06. On average, sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Vestal Point Capital LP grew its holdings in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after purchasing an additional 2,670,000 shares during the last quarter. Siren L.L.C. acquired a new position in Enliven Therapeutics in the 1st quarter valued at approximately $29,252,000. Affinity Asset Advisors LLC acquired a new position in Enliven Therapeutics in the 1st quarter valued at approximately $23,007,000. TCG Crossover Management LLC bought a new position in shares of Enliven Therapeutics during the second quarter valued at $9,990,000. Finally, Duquesne Family Office LLC lifted its holdings in shares of Enliven Therapeutics by 104.6% during the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after purchasing an additional 484,405 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ELVN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. The Goldman Sachs Group upped their price objective on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. HC Wainwright raised their price objective on Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. JonesTrading lifted their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, Guggenheim assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $67.83.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.